Paxlovid not linked to COVID rebound, FDA says.
- Advisers for the Food and Drug Administration are meeting Thursday to consider full approval for Pfizer’s Paxlovid.
The FDA gave the COVID-19 anti-viral emergency use authorization in 2021 for treating mild to moderate illness in high-risk adults.Some users had reported a return of symptoms and a positive COVID-19 test after finishing the five-day course of Paxlovid. However, clinical trial data has concluded that there is no clear association with a COVID-19 rebound.The FDA is expected to complete its review for approval in May.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA: Paxlovid Does Not Cause COVID ‘Rebound’The FDA says in a new report that rebound also occurs in people who did not take paxlovid—which can prevent COVID from becoming severe if given early enough—and appears to be part of the disease process in some.
Baca lebih lajut »
FDA: Paxlovid not associated with COVID reboundPaxlovid isn't associated with COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed, Food and Drug Administration staff said Tuesday.
Baca lebih lajut »
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Baca lebih lajut »
FDA panel to meet Thursday to discuss full approval of PaxlovidA Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill...
Baca lebih lajut »
FDA Staff Report Says Data Shows Pfizer's Covid Treatment Paxlovid Is Effective in High-Risk AdultsFDA staff said Pfizer’s clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.
Baca lebih lajut »
FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.
Baca lebih lajut »